Adaptive clinical trial designs seek to add flexibility to the fixed, linear “design-conduct-analyze” sequence of conventional clinic trials. Instead of assessing results after the trial is completed, adaptive designs allow for interim data reviews so that adjustments can be made during the study if warranted.
From refining sample size to adjusting dosing regimens, pre-defined trial components can be modified based on accumulating data to improve study efficiency. Adaptive designs can also head off ineffective trials before extensive time and cost is invested and decrease patient exposure to inefficacious therapies. This approach has the potential to drive smaller, shorter clinical trials and improve the likelihood of clinically relevant results.
Intervening in time based on biomarker insights
Biomarkers can play a critical role in enabling adaptive clinical trial designs, as they not only help to enroll patients most likely to benefit from the given treatment but can also be used to measure drug treatment effects in those patients throughout the trial, including clinical efficacy and toxicity responses.
Small molecule biomarkers are particularly well-suited for this application for several reasons. They are the most dynamic measures of biological processes and treatment response, and can therefore provide real-time information on the efficacy and safety of an intervention. Changes to a patient’s metabolome during the clinical trial can be detected early and may inform changes to their dosage, dosing schedule, or overall treatment protocol. Small molecule biomarkers can also readily traverse between tissue beds and blood so can often be captured via venipuncture. This provides a relatively non-invasive and cost-effective means for serial sampling and can support more frequent sampling over the course of the trial.
Case in point:
Adapting a clinical trial of combination therapy
Let’s use an example of a biomarker-guided clinical trial testing two anti-cancer drugs for a solid tumor. The first question to address is which drug, or combination of drugs, each patient should initially receive. Biomarkers can be identified at baseline that indicate individuals who are likely to be responsive to each specific treatment, and those response biomarkers can be measured in each patient at enrollment to determine their optimal therapeutic regimen. For example, one patient’s biomarker profile may indicate they are most likely to respond to anti-cancer drug A, while another patient’s profile indicates responsiveness to anti-cancer drug B.
Predictive biomarkers can be used to enrich a conventional clinical trial at enrollment, but they of course do not guarantee a favorable outcome for each patient. This is where adaptive clinical trial designs can potentially lead to greater efficacy and trial efficiency, as those biomarkers can also be monitored through the trial to understand if and how the patient is truly responding to treatment, and how interventions should be adjusted.
With interval profiling of patients’ small molecule biomarker signatures, we can obtain real-time readouts of different aspects of their underlying tumor composition and its sensitivity to each drug. These measures may indicate that the tumor has responded well to initial treatment with anti-cancer drug A, but now shows the propensity for an elevated response to anti-cancer drug B. As a tumor changes with treatment, the therapeutic combination and dosing strategy can be changed as well.
Frequent sampling and biomarker analysis can also help to identify patients who are non-responsive to treatment earlier in the trial, so higher dosages could be tested or those individuals can be removed from the study to limit unnecessary drug exposure.
The same discovery metabolomics approach used to capture biomarkers of treatment efficacy can also be applied to identify safety biomarkers for each therapy, with targeted profiling over the course of the trial to monitor for adverse events.
Equipped with these continual learnings, sponsors can monitor individual benefit-risk, modify trial arms to include subgroups with the most favorable response, reduce clinical trial size, and enable adaptive therapy to address the dynamics of complex disease.
Optimizing dosing and timing of treatments – and overall trial success
Small molecule biomarkers help support timely intervention to introduce, remove, increase, or combine therapies, and ultimately optimize trial outcomes. By applying these markers in an adaptive clinical trial design, ineffective treatments can be discontinued sooner and dose-response and dose-toxicity relationships in individual patients can be better understood to optimize dosing regimens. This approach can be applied to therapies individually or as combinations. The goal is to drive more efficient and informative clinical trials that require less patients but drive better outcomes with personalized therapies.
Sapient is ideally suited to support the discovery of baseline biomarkers of response and safety because of our high throughput, nontargeted technologies. We can screen samples from hundreds or thousands of people at a time, looking across broad chemistries to identify predictive biomarkers (whether known or unknown) of response to similar therapies. We can also reference our Human Biology Database, comprised of data from >100,000 samples from diverse individuals, to validate these predictive markers, and use our follow-on technology pipeline of traditional mass spectrometry systems for targeted screening of identified biomarkers in samples collected throughout the trial.
If you are interested in learning how Sapient can support your clinical trial strategies with high-throughput biomarker discovery as a service, feel free to reach out to us here.
Adaptive clinical trial designs seek to add flexibility to the fixed, linear “design-conduct-analyze” sequence of conventional clinic trials. Instead of assessing results after the trial is completed, adaptive designs allow for interim data reviews so that adjustments can be made during the study if warranted. From… Read More
Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker discovery and how next-generation mass spectrometry (MS)-based systems can help to fill the current gap in biomarker technologies. Read an excerpt from the… Read More
Understanding the risk factors that give rise to human disease is essential to early detection and development of effective treatments for disease prevention. Human disease risk represents an interaction between underlying genetic predisposition, which is largely set from the moment of conception, and the varied and changing exposures that occur… Read More
CNS diseases can have a wide range of symptoms which can make them difficult to diagnose and treat based on clinical presentation alone. Biomarkers can provide objective measures of the underlying disease process, which can help to distinguish between different subtypes of the disorder so that targeted therapies can be… Read More
Disease processes are complex. Individuals with the same genetic disorder, symptoms, and/or diagnosis can have varied prognosis and response to treatment. The mechanisms underlying disease can be quite different and may be influenced by a range of internal and external exposures experienced over time. Sensitive and… Read More
Sapient recently contributed a piece to Fierce Pharma discussing the new biological and disease insights that small molecule biomarkers can bring to improve drug development success – and how next-generation mass spectrometry is enabling their discovery on an entirely new scale. Excerpt: Dynamic organ physiology, inter-organ communication, host-disease interactions, and… Read More
Untargeted biomarker discovery aims to uncover previously unknown factors that associate with biologically relevant changes in human health and disease, such as those related to disease progression or treatment response. Most diseases, while singularly defined pathologically, actually represent diverse groupings of contributing factors and biological pathways. Identifying novel biomarkers can… Read More
Retrospective analyses conducted by major pharmaceutical companies on their drug pipelines have revealed that close to one-fifth of Phase II failures due to efficacy did not conclusively demonstrate adequate target exposure. This statistic emphasizes the importance of identifying target engagement biomarkers, which report on drug-target interactions… Read More
High throughput technologies can now capture and measure a huge number of biological molecules within a single human cell or tissue, enabling clearer and more complete views of underlying biology and supporting development of molecularly targeted drug therapies. These molecules are found at the gene, protein, and metabolic level, giving… Read More
Why are large, expensive clinical trials so common? It stems from the challenge of needing to demonstrate treatment efficacy in enough of the patient population despite the fact that a majority of patients are likely to be non-responders. The FDA generally expects at least 35% of… Read More